[1] 潘艳娟，王来海，张瑞岭，任明芬等．153例利培酮致精神分裂症患者心动过缓分析[J]．10.13286/j.cnki.chinhosppharmacyj.2018.08.09

[2] 余琳琳，舒孝萧，等．长期服用抗精神病药对心电图QTc（QT间期）影响的临床观察[J]．中国生化药物杂志，2017，37(10)：137—138．

[3] 曹莉莎，王继生，张芳，陈静，郭濠宁等．631例抗精神病药物药品不良反应分析[J]．中国药物警戒，2021

[4] Abdelmawla N, Mitchell AJ. Sudden cardiac death andantipsychotics. Part 2: Monitoring and prevention. AdvPsychiatr Treat 2006;12:100–9.

[5] Peter M. Haddad1 and Ian M. Anderson. Antipsychotic-Related QTc Prolongation,Torsade de Pointes and Sudden Death[J].10.2165/00003495-200262110-00006

[6] D Zhai，L Yan，G Dong，Y Liu，R Zhang，et al .QTc interval lengthening in first-episode schizophrenia (FES) patients in the earliest stages of antipsychotic

treatment.10.1016/j.schres.2016.10.006

[7] Miriam Jacoba Warnier,Frans Hendrik Rutten,Patrick Cyriel Souverein, Anthonius de Boer etal. Are ECG monitoring recommendations before prescription of QT‐prolonging drugs applied in daily practice? The example of haloperidol.10.1002/pds.3792

[8] Peter M. Haddad1 and Ian M. Anderson. Antipsychotic-Related QTc Prolongation,Torsade de Pointes and Sudden Death[J].10.2165/00003495-200262110-00006

[9] CS Wu，YT Tsai，HJ Tsai . Antipsychotic Drugs and the Risk of Ventricular Arrhythmia and/or Sudden Cardiac Death: A Nation‐wide Case‐Crossover Study. 10.1161/JAHA.114.001568

[10] Asim A Shah，Awais Aftab，John Coverdale . QTc Prolongation with Antipsychotics: Is Routine ECG Monitoring Recommended?10.1097/01.pra.0000450319.21859.6d

[11] De Hert M, Vancampfort D, Correll CU, et al. Guidelines for screening and monitoring of cardiometabolic risk inschizophrenia: Systematic evaluation. Br J Psychiatry2011;199:99–105.

[12] 吕建宝，曹文胜，康燕霞，韩瑞俊，李娟．精神分裂症患者QTc间期延长的影响因素[J]．中华心血管病杂志，2001，29(10)：618—621．

[13] 吴杰，JanAK，PeterRR，等．中国人群心电图时间参数的年龄和性别差异[J]．中10.3969/j.issn.1009-6574.2014.04.014

[14] 吴海云，王士雯．心血管疾病中的性别差异：当前亟需关注的几个问题[J]．中华老年多器官疾病杂志，2008，7(6)：452—455．

[15] 张有友，刘良，朱江涛，余亚蕾，张杰，等．常见抗精神病药物心血管毒性的研究进展[J]．中国法医学杂志，2020，35(1)：60—68．

[16]  TR Barnes，R Drake，C Paton，SJ Cooper，AR Yung. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology.10.1177/0269881119889296

[17] De Hert M, Vancampfort D, Correll CU, et al. Guidelines for screening and monitoring of cardiometabolic risk inschizophrenia: Systematic evaluation. Br J Psychiatry2011;199:99–105.

[18] Krasucki C, McFarlane F. Electrocardiograms, high-doseantipsychotic treatment and College guidelines. PsychiatrBull 1996;20:326–30.

[19] Perkins DO, Lieberman JA. Medical complications andselectivity of therapeutic response to atypical antipsychotic drugs. Am J Psychiatry 1998;155:272–6

[20] Fayek M, Kingsbury SJ, Zada J, et al. Psychopharma -cology: Cardiac effects of antipsychotic medications.Psychiatr Serv 2001;52:607–9

[21] Francis PD. Effects of psychotropic medications on thepediatric electrocardiogram and recommendations formonitoring. Curr Opin Pediatr 2002;14:224–30

[22] Taylor D. Ziprasidone in the management of schizophrenia: The QT interval issue in context. CNS Drugs 2003;17:423–30.

[23] Rettenbacher MA, Eder-Ischia U, Bader A, et al. QTc variability in schizophrenia patients treated with antipsychotics and healthy controls. J Clin Psychopharmacol2005;25:206–10

[24] Abdelmawla N, Mitchell AJ. Sudden cardiac death andantipsychotics. Part 2: Monitoring and prevention. AdvPsychiatr Treat 2006;12:100–9.

[25] NIF Health，C Excellence.Psychosis and schizophrenia in adults: treatment and management. NICE Clinical Guideline 178.2014

[26] SPC Haldol 5mg tablets.

[27] Solomon, M.D., Yang, J., Sung, S.H., Livingston, M.L., Sarlas, G., Lenane, J.C. and Go, A.S., 2016. Incidence and timing of potentially high-risk arrhythmias detected through long term continuous ambulatory electrocardiographic monitoring. BMC cardiovascular disorders, 16(1), pp.1-7.